ReviewDrug delivery and translational research2025
Advances in constructing biocompatible nanocarriers.
Review in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- Tumor Microenvironment-Responsive Polymeric Nanocarriers for the Treatment of Triple-Negative Breast Cancer.Pharmaceutics · 2026Review
- Omics-Based Functional Fingerprinting of Nanoparticles in Cancer: Toward Predictive Nanomedicine.International journal of molecular sciences · 2026Review
- Multifunctional rGO/YRSC advances · 2026Article
- Construction of chiral ZnO/BMP-2 dual functional coating on the surface of Ti implants for anti-infection and enhancement of osseointegration.Frontiers in bioengineering and biotechnology · 2026Article
- Quo Vadis translational neuroscience?Translational neuroscience · 2026Review
- Advances in ultrasound-assisted drug delivery and clinical application.Ultrasonics sonochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The design of effective drug nanocarriers requires the prevention of adverse biological interactions such as immune activation and cytotoxicity, making superior biocompatibility a critical determinant for clinical success. While existing reviews predominantly focus on the therapeutic applications of nanomedicines, systematic analyses of biocompatibility optimization strategies remain scarce. To address this gap, we present a review of three primary approaches for constructing biocompatible nanocarriers: (1) inert-material-based frameworks, (2) polymer surface engineering techniques, and (3) biomimetic functionalization methodologies. By evaluating the structural designs and biological mechanisms of commonly employed materials, we elucidated how these strategies leverage inherent material properties and biological interaction principles to regulate biocompatibility. Furthermore, we analyzed the advantages and limitations of each approach, offering guidance for selecting the optimal biocompatibility enhancement methods. This work not only synthesizes current advancements in biocompatible nanocarrier development but also provides actionable insights to advance nanomedicine research and clinical translation.
Indexed as
Identifiers
40531369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.